PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30683630-0	2019	Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.	lorlatinib	23-33	ROS proto-oncogene 1, receptor tyrosine kinase	Homo sapiens	92-96	
30683630-2	2019	Lorlatinib, a novel third-generation TKI, produced remarkable results from the first-in-man phase 1 trial: an overall response rate of 46% and 50% for previously treated ALK- and ROS1-positive patients, respectively.	lorlatinib	0-10	ROS proto-oncogene 1, receptor tyrosine kinase	Homo sapiens	179-183	
30683630-14	2019	CONCLUSION: This study is the first to report that lorlatinib is an important novel therapeutic option for Asian patients who have advanced NSCLC harboring ALK/ROS1 mutations whose disease progressed during treatment with first- and second-generation TKIs.	lorlatinib	51-61	ROS proto-oncogene 1, receptor tyrosine kinase	Homo sapiens	160-164